The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

Novo Nordisk is moving forward with plans to develop oral obesity drugs through a new partnership, which comes as longtime CEO Lars Fruergaard Jørgensen prepares to step down. The drugmaker launched a ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for ...

Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 ...